Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo standard primary (first-time) one-sided total hip replacement surgery due to degenerative joint disease (arthritis), not due to some inflammatory process, (eg. infection)~* Baseline pain intensity \>= 4 on an 11-point (0 to 10) Pain Intensity rating scale, rated within 30 minutes before randomization~* Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the study~Exclusion Criteria:~* Patients will be excluded from the study if they have a history of seizure disorder or epilepsy~* history of malignancy within the past 2 years before starting the study~* history of alcohol or drug abuse~* evidence of active infections that may spread to other areas of the body~* clinical laboratory values reflecting moderate or severe kidney insufficiency~* currently treated with anticonvulsants, monoamine oxidase inhibitors, tricyclic antidepressants, neuroleptics, or selective norepinephrine reuptake inhibitor (SNRI), (selective serotonin reuptake inhibitor \[SSRI\] treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 003 (Type: PLACEBO_COMPARATOR): Placebo Fixed Dose Matching placebo for 3 days
- 002 (Type: ACTIVE_COMPARATOR): Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
- 001 (Type: EXPERIMENTAL): Tapentadol IR (CG5503) Fixed Dose 50, 75, \& 100 mg BID for 3 days
- 004 (Type: OTHER): Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 \& 100 mg BID for 9 days

Based on this trial design, predict the completion outcome and termination type (if applicable).